AU2017261218A1 - Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxyacrylamide and uses thereof - Google Patents
Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxyacrylamide and uses thereof Download PDFInfo
- Publication number
- AU2017261218A1 AU2017261218A1 AU2017261218A AU2017261218A AU2017261218A1 AU 2017261218 A1 AU2017261218 A1 AU 2017261218A1 AU 2017261218 A AU2017261218 A AU 2017261218A AU 2017261218 A AU2017261218 A AU 2017261218A AU 2017261218 A1 AU2017261218 A1 AU 2017261218A1
- Authority
- AU
- Australia
- Prior art keywords
- benzoimidazol
- diethylamino
- butyl
- ethyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330673P | 2016-05-02 | 2016-05-02 | |
| US62/330,673 | 2016-05-02 | ||
| PCT/US2017/030414 WO2017192451A1 (en) | 2016-05-02 | 2017-05-01 | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017261218A1 true AU2017261218A1 (en) | 2018-11-29 |
Family
ID=60203321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017261218A Abandoned AU2017261218A1 (en) | 2016-05-02 | 2017-05-01 | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1H-benzoimidazol-5-yl]-N-hydroxyacrylamide and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10626092B2 (enExample) |
| EP (2) | EP3939966A1 (enExample) |
| JP (1) | JP2019514905A (enExample) |
| KR (1) | KR20190005904A (enExample) |
| CN (1) | CN109414425A (enExample) |
| AR (1) | AR108257A1 (enExample) |
| AU (1) | AU2017261218A1 (enExample) |
| BR (1) | BR112018072439A2 (enExample) |
| CA (1) | CA3022011A1 (enExample) |
| CL (1) | CL2018003109A1 (enExample) |
| CO (1) | CO2018012941A2 (enExample) |
| EA (1) | EA201892341A1 (enExample) |
| ES (1) | ES2886495T3 (enExample) |
| IL (1) | IL262578A (enExample) |
| MA (1) | MA44880A (enExample) |
| MX (1) | MX382095B (enExample) |
| PH (1) | PH12018502296B1 (enExample) |
| SG (1) | SG11201809471UA (enExample) |
| TW (1) | TW201741286A (enExample) |
| WO (1) | WO2017192451A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018157742A1 (zh) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Sb-939的盐的晶型及其制备方法和用途 |
| WO2019126282A1 (en) | 2017-12-19 | 2019-06-27 | Assia Chemical Industries Ltd. | Crystalline polymorphs of pracinostat and pracinostat salts |
| WO2019149262A1 (zh) * | 2018-02-05 | 2019-08-08 | 苏州科睿思制药有限公司 | Sb-939的晶型及其制备方法和用途 |
| US20230159468A1 (en) | 2020-04-22 | 2023-05-25 | Macfarlan Smith Limited | Novel forms of pracinostat dihydrochloride |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2291749A1 (fr) | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
| CA2135173A1 (en) | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Ester derivatives of 4-aza-steroids |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| US6329380B1 (en) | 1999-06-30 | 2001-12-11 | Merck & Co., Inc. | SRC kinase inhibitor compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| CN1358094A (zh) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | 用mek抑制剂治疗慢性疼痛的方法 |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| US6541661B1 (en) | 1999-11-23 | 2003-04-01 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| SK13752001A3 (sk) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| HUP0400651A2 (hu) | 2000-11-07 | 2004-06-28 | Bristol-Myers Squibb Company | Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| WO2003000682A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| CA2473505A1 (en) | 2002-02-07 | 2003-08-14 | Ellen M. Leahy | Novel bicyclic hydroxamates as inhibitors of histone deacetylase |
| CA2478534A1 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| AU2003231359B2 (en) | 2002-04-16 | 2009-04-30 | Teijin Limited | Piperidine derivatives having CCR3 antagonism |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| MY142589A (en) | 2003-09-22 | 2010-12-15 | S Bio Pte Ltd | Benzimidazole derivatives : preparation and pharmaceutical applications |
| WO2005066151A2 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050159470A1 (en) | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| CA2540459C (en) * | 2005-09-08 | 2014-02-18 | S*Bio Pte Ltd | Benzimidazole compounds and uses in treating proliferative disorders |
| PL1937650T3 (pl) * | 2005-09-08 | 2011-11-30 | Mei Pharma Inc | Związki heterocykliczne |
| EP2131840B1 (en) | 2007-03-07 | 2018-10-17 | MEI Pharma, Inc. | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| EP3662911A1 (en) | 2012-10-30 | 2020-06-10 | MEI Pharma, Inc. | Combination of azacitidine and pracinostat to treat myelodysplastic syndrome (mds) |
-
2017
- 2017-04-28 AR ARP170101104A patent/AR108257A1/es unknown
- 2017-05-01 ES ES17793075T patent/ES2886495T3/es active Active
- 2017-05-01 SG SG11201809471UA patent/SG11201809471UA/en unknown
- 2017-05-01 US US16/098,435 patent/US10626092B2/en not_active Expired - Fee Related
- 2017-05-01 MX MX2018013349A patent/MX382095B/es unknown
- 2017-05-01 EA EA201892341A patent/EA201892341A1/ru unknown
- 2017-05-01 AU AU2017261218A patent/AU2017261218A1/en not_active Abandoned
- 2017-05-01 MA MA044880A patent/MA44880A/fr unknown
- 2017-05-01 CA CA3022011A patent/CA3022011A1/en not_active Abandoned
- 2017-05-01 WO PCT/US2017/030414 patent/WO2017192451A1/en not_active Ceased
- 2017-05-01 CN CN201780041511.XA patent/CN109414425A/zh active Pending
- 2017-05-01 KR KR1020187034681A patent/KR20190005904A/ko not_active Abandoned
- 2017-05-01 JP JP2018555958A patent/JP2019514905A/ja active Pending
- 2017-05-01 EP EP21178272.7A patent/EP3939966A1/en not_active Withdrawn
- 2017-05-01 EP EP17793075.7A patent/EP3452035B1/en active Active
- 2017-05-01 BR BR112018072439-4A patent/BR112018072439A2/pt not_active IP Right Cessation
- 2017-05-02 TW TW106114551A patent/TW201741286A/zh unknown
-
2018
- 2018-10-24 IL IL262578A patent/IL262578A/en unknown
- 2018-10-29 PH PH12018502296A patent/PH12018502296B1/en unknown
- 2018-10-31 CL CL2018003109A patent/CL2018003109A1/es unknown
- 2018-11-29 CO CONC2018/0012941A patent/CO2018012941A2/es unknown
-
2020
- 2020-03-09 US US16/813,230 patent/US20200317621A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200317621A1 (en) | 2020-10-08 |
| EA201892341A1 (ru) | 2019-05-31 |
| CN109414425A (zh) | 2019-03-01 |
| BR112018072439A2 (pt) | 2019-02-19 |
| EP3452035A1 (en) | 2019-03-13 |
| PH12018502296B1 (en) | 2022-04-06 |
| ES2886495T3 (es) | 2021-12-20 |
| KR20190005904A (ko) | 2019-01-16 |
| JP2019514905A (ja) | 2019-06-06 |
| TW201741286A (zh) | 2017-12-01 |
| AR108257A1 (es) | 2018-08-01 |
| WO2017192451A1 (en) | 2017-11-09 |
| MX2018013349A (es) | 2019-02-20 |
| SG11201809471UA (en) | 2018-11-29 |
| PH12018502296A1 (en) | 2019-07-08 |
| EP3452035A4 (en) | 2019-09-25 |
| EP3939966A1 (en) | 2022-01-19 |
| IL262578A (en) | 2018-12-31 |
| US20190152923A1 (en) | 2019-05-23 |
| CA3022011A1 (en) | 2017-11-09 |
| CO2018012941A2 (es) | 2018-12-28 |
| MX382095B (es) | 2025-03-13 |
| MA44880A (fr) | 2021-03-17 |
| CL2018003109A1 (es) | 2019-04-26 |
| US10626092B2 (en) | 2020-04-21 |
| EP3452035B1 (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7379680B2 (ja) | テルフェニル化合物の新規な塩 | |
| JP6891322B2 (ja) | 製造方法及びｍｄｍ２阻害剤の結晶形 | |
| AU2019268583B2 (en) | Crystalline forms of a TLR7/TLR8 inhibitor | |
| US20200317621A1 (en) | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof | |
| JP7644027B2 (ja) | Ｂｔｋ阻害剤の結晶形態 | |
| EP3218351B1 (en) | A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377 | |
| JP2015522037A (ja) | ベムラフェニブコリン塩の固体形態 | |
| US20240228438A1 (en) | Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2- hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile | |
| US20210171460A1 (en) | Crystalline form of sofpironium bromide and preparation method thereof | |
| JP7068288B2 (ja) | ４－（２－（（１ｒ，２ｒ）－２－ヒドロキシシクロヘキシルアミノ）ベンゾチアゾール－６－イルオキシ）－ｎ－メチルピコリンアミドの結晶形 | |
| US8598201B2 (en) | Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride | |
| US8710078B2 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride | |
| RU2828460C2 (ru) | Кристаллические формы ингибитора btk | |
| EP3972960B1 (en) | Crystalline forms of a btk inhibitor | |
| CN118525011A (zh) | 一种吗啉基喹唑啉类化合物、其制备方法及应用 | |
| NZ620864B2 (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride | |
| HK1192546B (en) | Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ POLYMORPHIC FORMS OF 3-(2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL)-N-HYDROXYACRYLAMIDE AND USES THEREOF |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |